The favorable safety profile observed in this case aligns with the design rationale of cadonilimab, which aims to reduce peripheral toxicity mediated by CTLA-4 targeting through its unique structure (lacking Fc effector function and enriched in the tumor microenvironment). Here, CTLA4 is linked to neoplasm.